Effect of Cabergoline on Weight and Glucose Tolerance
The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults.
This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks.
The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.
|Body Weight Impaired Glucose Tolerance in Obese||Drug: Cabergoline Other: placebo||Phase 1 Phase 2|
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Participant, Investigator)
|Official Title:||Randomized Controlled Pilot Study of the Effect of Cabergoline on Body Weight and Glucose Tolerance in Healthy Obese Adults|
- body weight [ Time Frame: 16 weeks ]
- glucose [ Time Frame: 16 weeks ]
|Study Start Date:||April 2002|
|Study Completion Date:||July 2011|
|Primary Completion Date:||September 2003 (Final data collection date for primary outcome measure)|
Placebo Comparator: placebo
1 pill twice weekly
Active Comparator: cabergoline
cabergoline 0.5 mg twice weekly
Please refer to this study by its ClinicalTrials.gov identifier: NCT01395602
|United States, New York|
|New York, New York, United States, 10032|
|Principal Investigator:||Judith Korner, MD, PHD||Columbia University|